40 results on '"Brosius III, Frank C."'
Search Results
2. Transcriptional networks of murine diabetic peripheral neuropathy and nephropathy: common and distinct gene expression patterns
- Author
-
Hur, Junguk, O’Brien, Phillipe D., Nair, Viji, Hinder, Lucy M., McGregor, Brett A., Jagadish, Hosagrahar V., Kretzler, Matthias, Brosius, III, Frank C., and Feldman, Eva L.
- Published
- 2016
- Full Text
- View/download PDF
3. New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy
- Author
-
Brosius, III, Frank C.
- Published
- 2008
- Full Text
- View/download PDF
4. Glucose transporters in diabetic nephropathy
- Author
-
Brosius, III, Frank C. and Heilig, Charles W.
- Published
- 2005
- Full Text
- View/download PDF
5. Identification of cross-species shared transcriptional networks of diabetic nephropathy in human and mouse glomeruli
- Author
-
Hodgin, Jeffrey B., Nair, Viji, Zhang, Hongyu, Randolph, Ann, Harris, Raymond C., Nelson, Robert G., Weil, E. Jennifer, Cavalcoli, James D., Patel, Jignesh M., Brosius, III, Frank C., and Kretzler, Matthias
- Subjects
Kidney glomerulus -- Genetic aspects ,Cellular signal transduction -- Genetic aspects ,Genetic transcription -- Research ,Diabetic nephropathies -- Diagnosis -- Care and treatment ,Health - Abstract
Murine models are valuable instruments in defining the pathogenesis of diabetic nephropathy (DN), but they only partially recapitulate disease manifestations of human DN, limiting their utility. To define the molecular similarities and differences between human and murine DN, we performed a cross-species comparison of glomerular transcriptional networks. Glomerular gene expression was profiled in patients with early type 2 DN and in three mouse models (streptozotocin DBA/2, C57BLKS db/db, and eNOS-deficient C57BLKS db/db mice). Species-specific transcriptional networks were generated and compared with a novel network-matching algorithm. Three shared human-mouse cross-species glomerular transcriptional networks containing 143 (Human-DBA STZ), 97 (Human-BKS db/db), and 162 (Human-BKS [eNOS.sup.-/-] db/db) gene nodes were generated. Shared nodes across all networks reflected established pathogenic mechanisms of diabetes complications, such as elements of Janus kinase (JAK)/signal transducer and activator of transcription (STAT) and vascular endothelial growth factor receptor (VEGFR) signaling pathways. In addition, novel pathways not previously associated with DN and cross-species gene nodes and pathways unique to each of the human-mouse networks were discovered. The human-mouse shared glomerular transcriptional networks will assist DN researchers in selecting mouse models most relevant to the human disease process of interest. Moreover, they will allow identification of new pathways shared between mice and humans. Diabetes 62:299-308, 2013, Diabetic nephropathy (DN) is the leading cause of end-stage renal disease in the United States (1). Advances in the understanding of the pathogenesis of DN have revealed multiple genetic and [...]
- Published
- 2013
- Full Text
- View/download PDF
6. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy
- Author
-
Qian, Ying, Feldman, Eva, Pennathur, Subramanian, Kretzler, Matthias, and Brosius, III, Frank C.
- Subjects
Chronic kidney failure -- Development and progression -- Risk factors -- Research ,Cellular signal transduction -- Physiological aspects -- Research ,Diabetic nephropathies -- Development and progression -- Complications and side effects -- Research ,Health ,Complications and side effects ,Physiological aspects ,Development and progression ,Research ,Risk factors - Abstract
Progression of diabetic nephropathy to end-stage kidney disease is mediated by a host of processes, but none is as important as the gradual, inexorable scarring of the renal glomerulus, known [...]
- Published
- 2008
- Full Text
- View/download PDF
7. Evidence for a novel TGF-β1-independent mechanism of fibronectin production in mesangial cells overexpressing glucose transporters. (Complications)
- Author
-
Weigert, Cora, Brodbeck, Katrin, Brosius, III, Frank C., Huber, Matthias, Lehmann, Rainer, Friess, Ulrich, Facchin, Sonia, Aulwurm, Steffen, Haring, Hans U., Schleicher, Erwin D., and Heilig, Charles W.
- Subjects
Glucose metabolism -- Physiological aspects ,Transforming growth factors -- Physiological aspects ,Diabetic nephropathies -- Development and progression ,Health ,Physiological aspects ,Development and progression - Abstract
Recent experimental work indicates that the hyperglycemia-induced increase in mesangial matrix production, which is a hallmark in the development of diabetic nephropathy, is mediated by increased expression of GLUT1. Mesangial [...]
- Published
- 2003
8. D-glucose stimulates mesangial cell GLUT1 expression and basal and IGF-I-sensitive glucose uptake in rat mesangial cells: implications for diabetic nephropathy
- Author
-
Heilig, Charles W., Liu, Yanan, England, Rebecca L., Freytag, Svend O., Gilbert, Jeffery D., Heilig, Kathleen O., Zhu, Min, Concepcion, Luis A., and Brosius, III, Frank C.
- Subjects
Gene expression -- Research -- Health aspects ,Diabetes -- Research ,Blood sugar -- Health aspects -- Research ,Health ,Research ,Health aspects - Abstract
The complications of diabetes arise in part from abnormally high cellular glucose uptake and metabolism. To determine whether altered glucose transporter expression may be involved in the pathogenesis of diabetic [...]
- Published
- 1997
9. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation.
- Author
-
Tuttle, Katherine R., Brosius III, Frank C., Cavender, Matthew A., Fioretto, Paola, Fowler, Kevin J., Heerspink, Hiddo J.L., Manley, Tom, McGuire, Darren K., Molitch, Mark E., Mottl, Amy K., Perreault, Leigh, Rosas, Sylvia E., Rossing, Peter, Sola, Laura, Vallon, Volker, Wanner, Christoph, Perkovic, Vlado, and Brosius, Frank C 3rd
- Subjects
- *
SODIUM-glucose cotransporters , *TYPE 2 diabetes , *CARDIOVASCULAR diseases , *TECHNICAL reports , *SODIUM-glucose cotransporter 2 inhibitors , *CHRONIC kidney failure , *KIDNEY failure , *RESEARCH , *EDUCATION , *RESEARCH methodology , *MEDICAL cooperation , *EVALUATION research , *COMPARATIVE studies , *DIABETIC nephropathies , *DISEASE complications ,CHRONIC kidney failure complications - Abstract
Diabetes is the most frequent cause of chronic kidney disease (CKD), leading to nearly half of all cases of kidney failure requiring replacement therapy. The principal cause of death among patients with diabetes and CKD is cardiovascular disease (CVD). Sodium/glucose cotransporter 2 (SGLT2) inhibitors were developed to lower blood glucose levels by inhibiting glucose reabsorption in the proximal tubule. In clinical trials designed to demonstrate the CVD safety of SGLT2 inhibitors in type 2 diabetes mellitus (T2DM), consistent reductions in risks for secondary kidney disease end points (albuminuria and a composite of serum creatinine doubling or 40% estimated glomerular filtration rate decline, kidney failure, or death), along with reductions in CVD events, were observed. In patients with CKD, the kidney and CVD benefits of canagliflozin were established by the CREDENCE (Canagliflozin and Renal Events in Diabetes With Established Nephropathy Clinical Evaluation) trial in patients with T2DM, urinary albumin-creatinine ratio >300 mg/g, and estimated glomerular filtration rate of 30 to <90 mL/min/1.73 m2 To clarify and support the role of SGLT2 inhibitors for treatment of T2DM and CKD, the National Kidney Foundation convened a scientific workshop with an international panel of more than 80 experts. They discussed the current state of knowledge and unanswered questions in order to propose therapeutic approaches and delineate future research. SGLT2 inhibitors improve glomerular hemodynamic function and are thought to ameliorate other local and systemic mechanisms involved in the pathogenesis of CKD and CVD. SGLT2 inhibitors should be used when possible by people with T2DM to reduce risks for CKD and CVD in alignment with the clinical trial entry criteria. Important risks of SGLT2 inhibitors include euglycemic ketoacidosis, genital mycotic infections, and volume depletion. Careful consideration should be given to the balance of benefits and harms of SGLT2 inhibitors and risk mitigation strategies. Effective implementation strategies are needed to achieve widespread use of these life-saving medications. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
10. Regulation of mitochondrial dynamics and energetics in the diabetic renal proximal tubule by the β2-adrenergic receptor agonist formoterol.
- Author
-
Cleveland, Kristan H., Brosius III, Frank C., and Schnellmann, Rick G.
- Subjects
- *
PROXIMAL kidney tubules , *FORMOTEROL , *DIABETIC nephropathies , *MITOCHONDRIAL proteins , *ACUTE kidney failure , *MITOCHONDRIAL pathology , *METABOLIC disorders - Abstract
Regulation of mitochondrial dynamics and energetics in the diabetic renal proximal tubule by the b2-adrenergic receptor agonist formoterol. Am J Physiol Renal Physiol 319: F773-F779, 2020. First published September 21, 2020; doi:10.1152/ajprenal.00427.2020.--Diabetes is a prevalent metabolic disease that contributes to 50% of all endstage renal disease and has limited treatment options. We previously demonstrated that the b2-adrenergic receptor agonist formoterol induced mitochondrial biogenesis and promoted recovery from acute kidney injury. Here, we assessed the effects of formoterol on mitochondrial dysfunction and dynamics in renal proximal tubule cells (RPTCs) treated with high glucose and in a mouse model of type 2 diabetes. RPTCs exposed to 17 mM glucose exhibited increased electron transport chain (ETC) complex I, II, III, and V protein levels and reduced ATP levels and uncoupled oxygen consumption rate compared with RPTCs cultured in the absence of glucose or osmotic controls after 96 h. ETC proteins, ATP, and oxygen consumption rate were restored in RPTCs treated with formoterol. RPTCs exposed to high glucose had increased phosphodynamin- related protein 1 (Drp1), a mitochondrial fission protein, and decreased mitofusin 1 (Mfn1), a mitochondrial fusion protein. Formoterol treatment restored phospho-Drp1 and Mfn1 to control levels. Db/db and nondiabetic (db/m) mice (10 wk old) were treated with formoterol or vehicle for 3 wk and euthanized. Db/db mice showed increased renal cortical ETC protein levels in complexes I, III, and V and decreased ATP; these changes were prevented by formoterol. Phospho-Drp1 was increased and Mfn1 was decreased in db/db mice, and formoterol restored both to control levels. Together, these findings demonstrate that hyperglycemic conditions in vivo and exposure of RPTCs to high glucose similarly alter mitochondrial bioenergetic and dynamics profiles and that treatment with formoterol can reverse these effects. Formoterol may be a promising strategy for treating early stages of diabetic kidney disease. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
11. Mitochondrial uncoupling has no effect on microvascular complications in type 2 diabetes.
- Author
-
Hinder, Lucy M., Sas, Kelli M., O’Brien, Phillipe D., Backus, Carey, Kayampilly, Pradeep, Hayes, John M., Lin, Cheng-mao, Zhang, Hongyu, Shanmugam, Sumathi, Rumora, Amy E., Abcouwer, Steven F., Brosius III, Frank C., Pennathur, Subramaniam, and Feldman, Eva L.
- Published
- 2019
- Full Text
- View/download PDF
12. The Metabolic Syndrome and Microvascular Complications in a Murine Model of Type 2 Diabetes.
- Author
-
Junguk Hur, Dauch, Jacqueline R., Hinder, Lucy M., Hayes, John M., Backus, Carey, Pennathur, Subramaniam, Kretzler, Matthias, Brosius III, Frank C., and Feldman, Eva L.
- Subjects
DIABETES complications ,METABOLIC syndrome ,MICROCIRCULATION disorders ,HYPERGLYCEMIA ,GENE expression - Abstract
To define the components of the metabolic syndrome that contribute to diabetic polyneuropathy (DPN) in type 2 diabetes mellitus (T2DM), we treated the BKS db/db mouse, an established murine model of T2DM and the metabolic syndrome, with the thiazolidinedione class drug pioglitazone. Pioglitazone treatment of BKS db/db mice produced a significant weight gain, restored glycemic control, and normalized measures of serum oxidative stress and triglycerides but had no effect on LDLs or total cholesterol. Moreover, although pioglitazone treatment normalized renal function, it had no effect on measures of large myelinated nerve fibers, specifically sural or sciatic nerve conduction velocities, but significantly improved measures of small unmyelinated nerve fiber architecture and function. Analyses of gene expression arrays of large myelinated sciatic nerves from pioglitazone-treated animals revealed an unanticipated increase in genes related to adipogenesis, adipokine signaling, and lipoprotein signaling, which likely contributed to the blunted therapeutic response. Similar analyses of dorsal root ganglion neurons revealed a salutary effect of pioglitazone on pathways related to defense and cytokine production. These data suggest differential susceptibility of small and large nerve fibers to specific metabolic impairments associated with T2DM and provide the basis for discussion of new treatment paradigms for individuals with T2DM and DPN. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
13. JAK inhibition and progressive kidney disease.
- Author
-
Brosius III, Frank C. and John Cijiang He
- Published
- 2015
- Full Text
- View/download PDF
14. Evidence for a Novel TGF-β1−Independent Mechanism of Fibronectin Production in Mesangial Cells Overexpressing Glucose Transporters
- Author
-
Weigert, Cora, primary, Brodbeck, Katrin, additional, Brosius III, Frank C., additional, Huber, Matthias, additional, Lehmann, Rainer, additional, Friess, Ulrich, additional, Facchin, Sonia, additional, Aulwurm, Steffen, additional, Häring, Hans U., additional, Schleicher, Erwin D., additional, and Heilig, Charles W., additional
- Published
- 2003
- Full Text
- View/download PDF
15. Trophic Factors and Cytokines in Early Diabetic Glomerulopathy
- Author
-
Brosius III, Frank C., primary
- Published
- 2003
- Full Text
- View/download PDF
16. Persistent Myocardial Ischemia Increases GLUT1 Glucose Transporter Expression in Both Ischemic and Non-ischemic Heart Regions
- Author
-
Brosius, III, Frank C, primary, Liu, Yannan, additional, Nguyen, Ngoc, additional, Sun, DaQing, additional, Bartlett, John, additional, and Schwaiger, Markus, additional
- Published
- 1997
- Full Text
- View/download PDF
17. Podocyte-specific overexpression of GLUT1 surprisingly reduces mesangial matrix expansion in diabetic nephropathy in mice.
- Author
-
Hongyu Zhang, Schin, MaryLee, Saha, Jharna, Burke, Kathleen, Holzman, Lawrence B., Filipiak, Wanda, Saunders, Thomas, Minghui Xiang, Heilig, Charles W., and Brosius III, Frank C.
- Subjects
DIABETES ,DIABETIC nephropathies ,KIDNEY diseases ,GROWTH factors ,GLUCOSE ,MONOSACCHARIDES - Abstract
Increased expression of the facilitative glucose transporter, GLUT1, leads to glomerulopathy that resembles diabetic nephropathy, whereas prevention of enhanced GLUT1 expression retards nephropathy. While many of the GLUT1-mediated effects are likely due to mesangial cell effects, we hypothesized that increased GLUT1 expression in podocytes also contributes to the progression of diabetic nephropathy. Therefore, we generated two podocyte-specific GLUT1 transgenic mouse lines (driven by a podocin promoter) on a db/m C57BLKS background. Progeny of the two thunders were used to generate diabetic db/db and control db/m littermate mice. Immunoblots of glomerular lysates showed that transgenic mice had a 3.5-fold (line 1) and 2.1-fold (line 2) increase in GLUT1 content compared with wild-type mice. Both lines showed similar increases in fasting blood glucose and body weights at 24 wk of age compared with wild-type mice. Mesangial index (percent PAS-positive material in the mesangial tuft) increased 88% (line 1) and 75% (line 2) in the wild-type diabetic mice but only 48% (line 1) and 39% (line 2) in the diabetic transgenic mice (P < 0.05, transgenic vs. wild-type mice). This reduction in mesangial expansion was accompanied by a reduction in fibronectin accumulation, and vascular endothelial growth factor (VEGF) levels increased only half as much in the transgenic diabetic mice as in wild-type diabetic mice. Levels of nephrin, neph1, CD2AP, podocin, and GLUT4 were not significantly different in transgenic compared with wild-type mice. Taken together, increased podocyte GLUT1 expression in diabetic mice does not contribute to early diabetic nephropathy; surprisingly, it protects against mesangial expansion and fibronectin accumulation possibly by blunting podocyte VEGF increases. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
18. GLUT1-induced cFLIP expression promotes proliferation and prevents apoptosis in vascular smooth muscle cells.
- Author
-
Vesely, Eileen D., Heilig, Charles W., and Brosius III, Frank C.
- Subjects
PHYSIOLOGICAL effects of glucose ,VASCULAR smooth muscle ,MUSCLE cells ,GENE expression ,MESSENGER RNA ,APOPTOSIS prevention ,CELL proliferation ,ANTIGENS ,PHYSIOLOGY - Abstract
Enhanced expression of the facilitative glucose transporter, GLUT1, has been shown to inhibit apoptosis in several cell systems including vascular smooth muscle cells (VSMC5). A decrease in apoptosis could lead to increased VSMC numbers in neointimal and medial arterial layers under several pathologic conditions. The hypothesis underlying these studies is that GLUT 1 induces expression of antiapoptotic and prosurvival genes that increase VSMC survival. Transcriptomic analysis of A7r5 VSMCs, in which GLUT1 was acutely overexpressed, showed a 2.14-fold increase in c-FLICE inhibitory protein (cFLIP), which promotes cellular growth and prevents apoptosis through caspase 8 binding. We confirmed that overexpression of GLUT1 induced mRNA and protein expression of both the long and short isoforms of cFLIP (cFLIPL and cFLIPs) in primary and stable immortalized VSMC lines as well as in aortas from GLUT1 transgenic mice. Increased GLUT1 reduced VSMC death by more than twofold after serum withdrawal, as evidenced by decreased caspase 3 activity and Trypan blue exclusion studies. GLUT1 overexpression resulted in a greater than twofold increase in proliferating cell nuclear antigen expression and live cell numbers, consistent with augmented VSMC proliferation. Lentiviral knockdown of cFLIPL showed that cFLIPL was necessary for the proproliferative and antiapoptotic effects of GLUT1 overexpression. Taken together, these data suggest that GLUT1 induction of cFLTPL expression augments proliferation and prevents apoptosis in VSMCs. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
19. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy.
- Author
-
Hongyu Zhang, Jharna Saha, Jaeman Byun, Schin, MaryLee, Lorenz, Matthew, Kennedy, Robert T., Kretzler, Matthias, Feldman, Eva L., Pennathur, Subramaniam, and Brosius III, Frank C.
- Subjects
DIABETIC nephropathies ,STREPTOZOTOCIN ,EXTRACELLULAR matrix ,FIBRONECTINS ,DIABETES - Abstract
Recent studies suggest that thiazolidinediones ameliorate diabetic nephropathy (DN) independently of their effect on hyperglycemia. In the current study, we confirm and extend these findings by showing that rosiglitazone treatment prevented the development of DN and reversed multiple markers of oxidative injury in DBA/2J mice made diabetic by low- dose streptozotocin. These diabetic mice developed a 14.2-fold increase in albuminuria and a 53% expansion of renal glomerular extracellular matrix after 12 wk of diabetes. These changes were largely abrogated by administration of rosiglitazone beginning 2 wk after the completion of streptozotocin injections. Rosiglitazone had no effect on glycemic control. Rosiglitazone had similar effects on insulin-treated diabetic mice after 24 wk of diabetes. Podocyte loss and glomerular fibronectin accumulation, other markers of early DN, were prevented by rosiglitazone in both 12- and 24-wk diabetic models. Surprisingly, glomerular GLUT1 levels did not increase and nephrin levels did not decrease in the diabetic animals; neither changed with rosiglitazone. Plasma and kidney markers of protein oxidation and lipid peroxidation were significantly elevated in the 24-wk diabetic animals despite insulin treatment and were reduced to near-normal levels by rosiglitazone. Finally, urinary metabolites were markedly altered by diabetes. Of 1,988 metabolite features identified by electrospray ionization time of flight mass spectrometry, levels of 56 were altered more than twofold in the urine of diabetic mice. Of these, 21 were returned to normal by rosiglitazone. Thus rosiglitazone has direct effects on the renal glomerulus to reduce reactive oxygen species accumulation to prevent type 1 diabetic mice from development of DN. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
20. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.
- Author
-
Buller, Carolyn L., Loberg, Robert D., Ming-Hui Fan, Qihong Zhu, Park, James L., Vesely, Eileen, Ken Inoki, Kun-Liang Guan, and Brosius III, Frank C.
- Subjects
GLUCOSE ,GLYCOGEN synthase kinase-3 ,VASCULAR smooth muscle ,MUSCLE cells ,PHOSPHORYLATION - Abstract
Glucose transport is a highly regulated process and is dependent on a variety of signaling events. Glycogen synthase kinase-3 (GSK-3) has been implicated in various aspects of the regulation of glucose transport, but the mechanisms by which GSK-3 activity affects glucose uptake have not been well defined. We report that basal glycogen synthase kinase-3 (GSK-3) activity regulates glucose transport in several cell types. Chronic inhibition of basal GSK-3 activity (8-24 h) in several cell types, including vascular smooth muscle cells, resulted in an approximately twofold increase in glucose uptake due to a similar increase in protein expression of the facilitative glucose transporter 1 (GLUT1). Conversely, expression of a constitutively active form of GSK-3β resulted in at least a twofold decrease in GLUT1 expression and glucose uptake. Since GSK-3 can inhibit mammalian target of rapamycin (mTOR) signaling via phosphorylation of the tuberous sclerosis complex subunit 2 (TSC2) tumor suppressor, we investigated whether chronic GSK-3 effects on glucose uptake and GLUT1 expression depended on TSC2 phosphorylation and TSC inhibition of mTOR. We found that absence of functional TSC2 resulted in a 1.5-to 3-fold increase in glucose uptake and GLUT1 expression in multiple cell types. These increases in glucose uptake and GLUT1 levels were prevented by inhibition of mTOR with rapamycin. GSK-3 inhibition had no effect on glucose uptake or GLUT1 expression in TSC2 mutant cells, indicating that GSK-3 effects on GLUT1 and glucose uptake were mediated by a TSC2/mTOR-dependent pathway. The effect of GSK-3 inhibition on GLUT1 expression and glucose uptake was restored in TSC2 mutant cells by transfection of a wild-type TSC2 vector, but not by a TSC2 construct with mutated GSK-3 phosphorylation sites. Thus, TSC2 and rapamycin-sensitive mTOR function downstream of GSK-3 to modulate effects of GSK-3 on glucose uptake and GLUT1 expression. GSK-3 therefore suppresses glucose uptake via TSC2 and mTOR and may serve to match energy substrate utilization to cellular growth. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
21. Hypoxia-inducible factor-1alpha is a critical mediator of hypoxia induced apoptosis in cardiac H9c2 and kidney epithelial HK-2 cells.
- Author
-
Malhotra, Ricky, Tyson, David W., Rosevear, Henry M., and Brosius III, Frank C.
- Subjects
TRANSCRIPTION factors ,APOPTOSIS ,HYPOXEMIA ,HEART cells ,EPITHELIAL cells ,KIDNEY tubules - Abstract
Background: Hypoxia inducible factor-1 (HIF-1) is a transcription factor that functions to maintain cellular homeostasis in response to hypoxia. There is evidence that HIF-1 can also trigger apoptosis, possibly when cellular responses are inadequate to meet energy demands under hypoxic conditions. Methods: Cardiac derived H9c2 and renal tubular epithelial HK-2 cells expressing either the wild type oxygen regulated subunit of HIF-1 (pcDNA3-Hif-1α) or a dominant negative version that lacked both DNA binding and transactivation domains (pcDNA3-DN-Hif-1α), were maintained in culture and exposed to hypoxia. An RNA interference approach was also employed to selectively knockdown expression of Hif-1α. Apoptosis was analyzed in both H9c2 and HK-2 cells by Hoechst and TUNEL staining, caspase 3 activity assays and activation of pro-apoptotic Bc12 family member Bax. Results: Overexpression of pcDNA3-DN-Hif-1α led to a significant reduction in hypoxia -induced apoptosis (17 ± 2%, P < 0.01) in H9c2 cells compared to both control-transfected and wild type Hif-1α transfected cells. Moreover, selective ablation of HIF-1α protein expression by RNA interference in H9c2 cells led to 55% reduction of caspase 3 activity and 46% reduction in the number of apoptotic cells as determined by Hoechst 33258 staining, after hypoxia. Finally, upregulation of the pro-apoptotic protein, Bax, was found in H9c2 cells overexpressing full-length pcDNA3-HA-HIF-1α exposed to hypoxia. In HK-2 cells overexpression of wild-type Hif-1α led to a two-fold increase in Hif-1α levels during hypoxia. This resulted in a 3.4-fold increase in apoptotic cells and a concomitant increase in caspase 3 activity during hypoxia when compared to vector transfected control cells. HIF-1α also induced upregulation of Bax in HK-2 cells. In addition, introduction of dominant negative Hif-1α constructs in both H9c2 and HK-2 -cells led to decreased active Bax expression. Conclusion: These data demonstrate that HIF-1α is an important component of the apoptotic signaling machinery in the two cell types. [ABSTRACT FROM AUTHOR]
- Published
- 2008
- Full Text
- View/download PDF
22. Podocyte specific knock out of selenoproteins does not enhance nephropathy in streptozotocin diabetic C57BL/6 mice.
- Author
-
Blauwkamp, Marsha N., Jingcheng Yu, Schin, MaryLee A., Burke, Kathleen A., Berry, Marla J., Carlson, Bradley A., Brosius III, Frank C., and Koenig, Ronald J.
- Subjects
SELENOPROTEINS ,DIABETIC nephropathies ,DIABETES complications ,OXIDATIVE stress ,STREPTOZOTOCIN ,LABORATORY mice - Abstract
Background: Selenoproteins contain selenocysteine (Sec), commonly considered the 21st genetically encoded amino acid. Many selenoproteins, such as the glutathione peroxidases and thioredoxin reductases, protect cells against oxidative stress by functioning as antioxidants and/or through their roles in the maintenance of intracellular redox balance. Since oxidative stress has been implicated in the pathogenesis of diabetic nephropathy, we hypothesized that selenoproteins protect against this complication of diabetes. Methods: C57BL/6 mice that have a podocyte-specific inability to incorporate Sec into proteins (denoted in this paper as PodoTrsp
-/- ) and control mice were made diabetic by intraperitoneal injection of streptozotocin, or were injected with vehicle. Blood glucose, body weight, microalbuminuria, glomerular mesangial matrix expansion, and immunohistochemical markers of oxidative stress were assessed. Results: After 3 and 6 months of diabetes, control and PodoTrsp-/- mice had similar levels of blood glucose. There were no differences in urinary albumin/creatinine ratios. Periodic acid-Schiff staining to examine mesangial matrix expansion also demonstrated no difference between control and PodoTrsp-/- mice after 6 months of diabetes, and there were no differences in immunohistochemical stainings for nitrotyrosine or NAD(P)H dehydrogenase, quinone 1. Conclusion: Loss of podocyte selenoproteins in streptozotocin diabetic C57BL/6 mice does not lead to increased oxidative stress as assessed by nitrotyrosine and NAD(P)H dehydrogenase, quinone 1 immunostaining, nor does it lead to worsening nephropathy. [ABSTRACT FROM AUTHOR]- Published
- 2008
- Full Text
- View/download PDF
23. Role for GLUT1 in diabetic glomerulosclerosis.
- Author
-
Heilig, Charles W., Brosius III, Frank C., and Cunningham, Carol
- Abstract
Numerous studies have investigated specific pathways that link diabetes and high extracellular glucose exposure to glomerulosclerosis and mesangial cell extracellular matrix production. However, only in the past ten years has a role for glucose transporters in this process been addressed. Many different glucose transporters are expressed in glomeruli; of these, the GLUT1 facilitative glucose transporter is upregulated in the diabetic renal cortex and in response to glomerular hypertension, as well as in cultured mesangial cells exposed to high glucose. Transgenic mouse and cell models have recently been developed to test the role of GLUT1 in the pathogenesis of glomerulosclerosis with and without diabetes. Clinical studies of GLUT1 alleles performed in humans have identified GLUT1 susceptibility alleles for diabetic nephropathy. Studies are also currently under way to assess the potential role of GLUT1 in nondiabetic renal disorders. [ABSTRACT FROM PUBLISHER]
- Published
- 2006
- Full Text
- View/download PDF
24. Reduction in podocyte density as a pathologic feature in early diabetic nephropathy in rodents: Prevention by lipoic acid treatment.
- Author
-
Siu, Brian, Saha, Jharna, Smoyer, William E., Sullivan, Kelli A., and Brosius III, Frank C.
- Subjects
MEDICAL research ,DIABETIC nephropathies ,LIPOIC acid ,DIABETES ,NEPHROLOGY ,THERAPEUTICS - Abstract
Background: A reduction in the number of podocytes and podocyte density has been documented in the kidneys of patients with diabetes mellitus. Additional studies have shown that podocyte injury and loss occurs in both diabetic animals and humans. However, most studies in animals have examined relatively long-term changes in podocyte number and density and have not examined effects early after initiation of diabetes. We hypothesized that streptozotocin diabetes in rats and mice would result in an early reduction in podocyte density and that this reduction would be prevented by antioxidants. Methods: The number of podocytes per glomerular section and the podocyte density in glomeruli from rats and mice with streptozotocin (STZ)-diabetes mellitus was determined at several time points based on detection of the glomerular podocyte specific antigens, WT-1 and GLEPP1. The effect of insulin administration or treatment with the antioxidant, a-lipoic acid, on podocyte number was assessed. Results: Experimental diabetes resulted in a rapid decline in apparent podocyte number and podocyte density. A significant reduction in podocytes/glomerular cross-section was found in STZ diabetes in rats at 2 weeks (14%), 6 weeks (18%) and 8 weeks (34%) following STZ injection. Similar declines in apparent podocyte number were found in STZ diabetes in C57BL/6 mice at 2 weeks, but not at 3 days after injection. Treatment with a-lipoic acid substantially prevented podocyte loss in diabetic rats but treatment with insulin had only a modest effect. Conclusion: STZ diabetes results in reduction in apparent podocyte number and in podocyte density within 2 weeks after onset of hyperglycemia. Prevention of these effects with antioxidant therapy suggests that this early reduction in podocyte density is due in part to increased levels of reactive oxygen species as well as hyperglycemia. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
25. Glucose transporter-1-deficient mice exhibit impaired Development and deformities that are similar to diabetic embryopathy.
- Author
-
Heiling, Charles W., Saunders, Thomas, Brosius III., Frank C., Moley, Kelle, Heilig, Kathleen, Baggs, Raymond, Guo, LiRong, and Conner, David
- Subjects
HYPERGLYCEMIA ,DIABETES ,LABORATORY mice ,EMBRYOS ,GLUCOSE ,CELL division ,APOPTOSIS ,ANENCEPHALY - Abstract
The hyperglycemia of maternal diabetes suppresses the glucose transporter-1 (GLUT1) facilitative glucose transporter 49-66% in preimplantation embryos. Glucose uptake is reduced and apoptosis is activated. We hypothesized that the reduction of embryonic GLUT1 may play a key role in the malformations of diabetic embryopathy. Therefore, we produced GLUT1-deficient transgenic mice [i.e., antisense-GLUT1 (GTIA5)] to determine whether GLUT1 deficiency alone could reproduce the growth defects. Early cell division of fertilized mouse eggs injected with GT1AS was markedly impaired; P < 0.001 vs. controls. Two populations of preimplantation embryos obtained from GT1AS x GT1AS heterozygote matings exhibited reduction of the 2-deoxyglucose uptake rate: one by 50% (presumed heterozygotes, P < 0.001 vs. control) and the other by 95% (presumed homozygotes, P < 0.001 vs. heterozygotes). Embryonic GLUT1 deficiency in the range reported with maternal diabetes was associated with growth retardation and developmental malformations similar to those described in diabetes-exposed embryos: intrauterine growth retardation (31.1%), caudal regression (9.8%), anencephaly with absence of the head (6.6%), microphthalmia (4.9%), and micrognathia (1.6%). Reduced body weight !(small embryos, <70% of the nontransgenic body weight) was accompanied by other malformations and a 56% reduction of GLUT1 protein, P < 0.001 vs. nonsmall embryos (body weight ≥70% normal). The heart, brain, and kidneys of embryonic day 18.5 GT1AS embryos exhibited 24-51% reductions of GLUT1 protein. The homozygous GT1A5 genotype was lethal during gestation. Reduced embryonic GLUT1 was associated with the appearance of apoptosis. Therefore, GLUT1 deficiency may play a role in producing embryonic malformations resulting from the hyperglycemia of maternal diabetes. Late gestational macrosomia was absent, apparently requiring a different mechanism. [ABSTRACT FROM AUTHOR]
- Published
- 2003
- Full Text
- View/download PDF
26. Hypoxia induces apoptosis via two independent pathways in Jurkat cells: differential regulation....
- Author
-
Malhotra, Ricky, Zhiwu Lin, Vincenz, Claudius, and Brosius III, Frank C.
- Subjects
APOPTOSIS ,HYPOXEMIA - Abstract
Examines the inducement of apoptosis by hypoxia via independent pathways in Jurkat cells. Methods in the conduct of the study; Role of glucose in prevention of cytochrome c releases and activation of caspase 9; Attenuation of hypoxia-induced cell death in Jurkat cells in the presence of glucose.
- Published
- 2001
- Full Text
- View/download PDF
27. Inability of Serotonin to Activate the c-Jun N-terminal Kinase and p38 Kinase Pathways in Rat Aortic Vascular Smooth Muscle Cells.
- Author
-
Banes, Amy K. L., Loberg, Robert D., Brosius III, Frank C., and Watts, Stephanie W.
- Subjects
SEROTONIN ,JNK mitogen-activated protein kinases ,PROTEIN kinases ,VASCULAR smooth muscle ,AORTA ,IMMUNOGLOBULINS ,LABORATORY rats - Abstract
Background: Serotonin (5-HT, 5-hydroxytryptamine) activates the Extracellular Signal-Regulated Kinase (ERK)/ Mitogen-Activated Protein Kinase (MAPK) pathways, in vascular smooth muscle cells. Parallel MAPK pathways, the c-Jun N-terminal Kinase (JNK) and p38 pathway, are activated by stimulators of the ERK/MAPK pathway. We hypothesized that 5-HT would activate the JNK and p38 pathways in rat vascular smooth muscle cells. Results: Results were determined using standard Western analysis and phosphospecific JNK and p38 antibodies. No significant activation by 5-HT (10
-9 - 10-5 M; 30 min) of the JNK or p38 pathways, as measured by protein phosphorylation, was observed in any of these experiments. These experiments were repeated in the presence of the serine/threonine phosphatase inhibitor okadaic acid (1 uM) and the tyrosine phosphatase inhibitor sodium orthovanadate (1 uM) to maximize any observable signal. Even under these optimized conditions, no activation of the JNK or p38 pathways by 5-HT was observed. Time course experiments (5-HT 10-5 M; 5 min, 15 min, 30 min and 60 min) showed no significant activation of JNK after incubation with 5-HT at any time point. However, we detected strong activation of JNK p54 and p46 (5- and 7 fold increases in bands p54 and p46, respectively over control levels) by anisomycin (500 ng/ml, 30 min). Similarly, a JNK activity assay failed to reveal activation of JNK by 5-HT, in contrast to the strong stimulation by anisomycin. Conclusion: Collectively, these data support the conclusion that 5-HT does not activate the JNK or p38 pathways in rat vascular smooth muscle cells. [ABSTRACT FROM AUTHOR]- Published
- 2001
- Full Text
- View/download PDF
28. AE anion exchanger mRNA and protein expression in vascular smooth muscle cells, aorta, and renal...
- Author
-
Brosius III, Frank C. and Pisoni, Ronald L.
- Subjects
- *
ANIONS , *ION exchange (Chemistry) , *PROTEINS , *VASCULAR smooth muscle , *KIDNEY blood-vessels - Abstract
Describes the characteristics of the AE anion exchanger mRNA and protein expression in vascular smooth muscle cells (VSMC), aorta and renal microvessels. Expression of AE isoforms in cultured VSMC and in rat blood vessels; AE transcript expression in vascular smooth muscle; Ribonuclease protection analysis of AE3 in aorta.
- Published
- 1997
- Full Text
- View/download PDF
29. Regional and segmental localization of AE2 anion exchanger mRNA and protein in rat kidney.
- Author
-
Brosius III, Frank C. and Nguyen, Khanh
- Subjects
- *
MESSENGER RNA , *KIDNEY tubules - Abstract
Reports that AE2 messenger RNA is detectable throughout the nephron, with maximal levels in the medullary thick ascending limb, approximately twice the level in the proximal tubule. Compatibility with the postulated roles of AE2 in the maintenance of intracellular pH and chloride concentration and with its possible participation in transepithelial transport.
- Published
- 1995
- Full Text
- View/download PDF
30. Altered renal expression of the insulin-responsive glucose transporter GLUT4 in experimental diabetes mellitus.
- Author
-
MARCUS, ROY G., ENGLAND, REBECCA, NGUYEN, KHANH, CHARRON, MAUREEN J., BRIGGS, JOSIE P., and BROSIUS III, FRANK C.
- Published
- 1994
31. Differential Effects of Empagliflozin on Microvascular Complications in Murine Models of Type 1 and Type 2 Diabetes.
- Author
-
Eid, Stephanie A., O'Brien, Phillipe D., Hinder, Lucy M., Hayes, John M., Mendelson, Faye E., Zhang, Hongyu, Zeng, Lixia, Kretzler, Katharina, Narayanan, Samanthi, Abcouwer, Steven F., Brosius III, Frank C., Pennathur, Subramaniam, Savelieff, Masha G., and Feldman, Eva L.
- Subjects
TYPE 1 diabetes ,TYPE 2 diabetes ,SODIUM-glucose cotransporters ,GLYCEMIC index ,EMPAGLIFLOZIN ,GLYCEMIC control ,SODIUM-glucose cotransporter 2 inhibitors - Abstract
Simple Summary: Type 1 and type 2 diabetes can lead to serious health problems that affect many organs including the nerve, the eye, and the kidney. These health problems can be disabling or even life-threatening, and to date, there are no effective therapies that can slow or prevent their development. We studied the effect of empagliflozin, a medication that reduces blood sugar levels and the risk of cardiovascular disease, on the nerve, eye, and kidney in a side-by-side comparison of type 1 and type 2 mouse models. Empagliflozin had no beneficial effects on disease progression in type 2 diabetic mice, but improved nerve function in the type 1 diabetic model, an effect that was accompanied by reduced markers of oxidative injury. These findings support the concept that different mechanisms contribute to nerve damage in type 1 and type 2 diabetes. Our results further support our view that the concept of one therapy will benefit all complications should be abandoned as we pursue more personalized, tissue-specific, diabetes type-specific treatments. Microvascular complications account for the significant morbidity associated with diabetes. Despite tight glycemic control, disease risk remains especially in type 2 diabetes (T2D) patients and no therapy fully prevents nerve, retinal, or renal damage in type 1 diabetes (T1D) or T2D. Therefore, new antidiabetic drug classes are being evaluated for the treatment of microvascular complications. We investigated the effect of empagliflozin (EMPA), an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), on diabetic neuropathy (DPN), retinopathy (DR), and kidney disease (DKD) in streptozotocin-induced T1D and db/db T2D mouse models. EMPA lowered blood glycemia in T1D and T2D models. However, it did not ameliorate any microvascular complications in the T2D model, which was unexpected, given the protective effect of SGLT2 inhibitors on DKD progression in T2D subjects. Although EMPA did not improve DKD in the T1D model, it had a potential modest effect on DR measures and favorably impacted DPN as well as systemic oxidative stress. These results support the concept that glucose-centric treatments are more effective for DPN in T1D versus T2D. This is the first study that provides an evaluation of EMPA treatment on all microvascular complications in a side-by-side comparison in T1D and T2D models. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
32. How glucose and glucose transporters protect cardiac myocytes
- Author
-
Brosius III, Frank C.
- Published
- 2003
- Full Text
- View/download PDF
33. Bordetella bronchiseptica pneumonia in a patient with chronic lymphocytic leukemia.
- Author
-
BUGGY, BRIAN P., BROSIUS III, FRANK C., BOGIN, ROBERT M., KOLLER, CHARLES A., SCHABERG, DENNIS R., Buggy, B P, Brosius, F C 3rd, Bogin, R M, Koller, C A, and Schaberg, D R
- Published
- 1987
- Full Text
- View/download PDF
34. The deacylase sirtuin 5 reduces malonylation in nonmitochondrial metabolic pathways in diabetic kidney disease.
- Author
-
Baek, Judy, Sas, Kelli, Chenchen He, Nair, Viji, Giblin, William, Inoki, Ayaka, Inoki, Yang Yingbao, Hodgin, Jeffrey, Nelson, Robert G., Brosius III, Frank C., Kretzler, Matthias, Stemmer, Paul M., Lombard, David B., and Pennathur, Subramaniam
- Subjects
- *
DIABETIC nephropathies , *KIDNEY cortex , *FATTY acid oxidation , *POST-translational modification , *SIRTUINS , *GLYCOLYSIS , *PROTEOMICS - Abstract
Early diabetic kidney disease (DKD) is marked by dramatic metabolic reprogramming due to nutrient excess, mitochondrial dysfunction, and increased renal energy requirements from hyperfiltration. We hypothesized that changes in metabolism in DKD may be regulated by Sirtuin 5 (SIRT5), a deacylase that removes posttranslational modifications derived from acyl-coenzyme A and has been demonstrated to regulate numerous metabolic pathways. We found decreased malonylation in the kidney cortex (-80% proximal tubules) of type 2 diabetic BKS db/db mice, associated with increased SIRT5 expression. We performed a proteomics analysis of malonylated peptides and found that proteins with significantly decreased malonylated lysines in the db/db cortex were enriched in nonmitochondrial metabolic pathways: glycolysis and peroxisomal fatty acid oxidation. To confirm relevance of these findings in human disease, we analyzed diabetic kidney transcriptomic data from a cohort of Southwestern American Indians, which revealed a tubulointerstitial-specific increase in Sirt5 expression. These data were further corroborated by immunofluorescence data of SIRT5 from nondiabetic and DKD cohorts. Furthermore, overexpression of SIRT5 in cultured human proximal tubules demonstrated increased aerobic glycolysis. Conversely, we observed reduced glycolysis with decreased SIRT5 expression. These findings suggest that SIRT5 may lead to differential nutrient partitioning and utilization in DKD. Taken together, our findings highlight a previously unrecognized role for SIRT5 in metabolic reprogramming in DKD. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. Myeloperoxidase-derived oxidants damage artery wall proteins in an animal model of chronic kidney disease-accelerated atherosclerosis.
- Author
-
Lixia Zeng, Mathew, Anna V., Byun, Jaeman, Atkins, Kevin B., Brosius III, Frank C., and Pennathur, Subramaniam
- Subjects
- *
MYELOPEROXIDASE , *CHRONIC kidney failure , *CARDIOVASCULAR diseases , *LOW density lipoproteins , *ARTERIOSCLEROSIS - Abstract
Increased myeloperoxidase (MPO) levels and activity are associated with increased cardiovascular risk among individuals with chronic kidney disease (CKD). However, a lack of good animal models for examining the presence and catalytic activity of MPO in vascular lesions has impeded mechanistic studies into CKD-associated cardiovascular diseases. Here, we show for the first time that exaggerated atherosclerosis in a pathophysiologically relevant CKD mouse model is associated with increased macrophage-derived MPO activity. Male 7-week-old LDL receptor-deficient mice underwent sham (control mice) or 5/6 nephrectomy and were fed either a low-fat or high-fat, highcholesterol diet for 24 weeks, and the extents of atherosclerosis and vascular reactivity were assessed. MPO expression and oxidation products-protein-bound oxidized tyrosine moieties 3-chlorotyrosine, 3-nitrotyrosine, and o,o'-dityrosine-were examined with immunoassays and confirmed with mass spectrometry (MS). As anticipated, the CKD mice had significantly higher plasma creatinine, urea nitrogen, and intact parathyroid hormone along with lower hematocrit and body weight.Onboth the diet regimens, CKD mice did not have hypertension but had lower cholesterol and triglyceride levels than the control mice. Despite the lower cholesterol levels, CKD mice had increased aortic plaque areas, fibrosis, and luminal narrowing. They also exhibited increased MPO expression and activity (i.e. increased oxidized tyrosines) that co-localized with infiltrating lesional macrophages and diminished vascular reactivity. In summary, unlike non-CKD mouse models of atherosclerosis, CKD mice exhibit increased MPO expression and catalytic activity in atherosclerotic lesions, which co-localize with lesional macrophages. These results implicate macrophage-derived MPO in CKD-accelerated atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
36. GLUT1-deficient mice exhibit impaired endothelium-dependent vascular relaxation
- Author
-
Park, James L., Heilig, Charles W., and Brosius III, Frank C.
- Subjects
- *
HYPOTHESIS , *EPITHELIUM , *RNA , *NUCLEIC acids - Abstract
We tested the hypothesis that decreased glucose transporter 1 (GLUT1) expression alters endothelial function. Nitric oxide-dependent endothelial relaxation, but not endothelium-independent relaxation, was significantly reduced in aortas from transgenic mice expressing GLUT1 antisense mRNA, compared to aortas from nontransgenic littermates. These data suggest that GLUT1-dependent glucose metabolism may play an important role in regulating endothelial function. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
37. Hypotension, lipodystrophy, and insulin resistance in generalized PPAR?-deficient mice rescued from embryonic lethality.
- Author
-
Sheng Zhong Duan, Ivashchenko, Christine Y., Whitesall, Steven E., D'Alecy, Louis G., Duquaine, Damon C., Brosius III, Frank C., Gonzalez, Frank J., Vinson, Charles, Pierre, Melissa A., Milstone, David S., and Mortensen, Richard M.
- Subjects
- *
INSULIN resistance , *HYPOTENSION , *BLOOD circulation disorders , *LABORATORY mice , *PHOSPHORYLATION , *ADRENERGIC alpha blockers - Abstract
We rescued the embryonic lethality of global PPARγ knockout by breeding Mox2-Cre (MORE) mice with floxed PPARγ mice to inactivate PPARγ in the embryo but not in trophoblasts and created a generalized PPARγ knockout mouse model, MORE-PPARγ knockout (MORE-PGKO) mice. PPARγ inactivation caused severe lipodystrophy and insulin resistance; surprisingly, it also caused hypotension. Paradoxically, PPARγ agonists had the same effect. We showed that another mouse model of lipodystrophy was hypertensive, ruling out the lipodystrophy as a cause. Further, high salt loading did not correct the hypotension in MORE-PGKO mice. In vitro studies showed that the vasculature from MORE-PGKO mice was more sensitive to endothelial-dependent relaxation caused by muscarinic stimulation, but was not associated with changes in eNOS expression or phosphorylation. In addition, vascular smooth muscle had impaired contraction in response to α-adrenergic agents. The renin-angiotensin-aldosterone system was mildly activated, consistent with increased vascular capacitance or decreased volume. These effects are likely mechanisms contributing to the hypotension. Our results demonstrated that PPARγ is required to maintain normal adiposity and insulin sensitivity in adult mice. Surprisingly, genetic loss of PPARγ function, like activation by agonists, lowered blood pressure, likely through a mechanism involving increased vascular relaxation. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
38. Targeted Disruption of the PEPT2 Gene Markedly Reduces Dipeptide Uptake in Choroid Plexus.
- Author
-
Hong Shen, Smith, David E., Keep, Richard F., Jianming Xiang, and Brosius III, Frank C.
- Subjects
- *
CHOROID plexus , *PEPTIDES , *MICE - Abstract
Demonstrates that targeted disruption of the PEPT2 transporter gene reduces dipeptide uptake in the choroid plexus of mice. Experimental procedures; Role of PEPT2 in the trafficking of peptides/mimetics at the blood-cerebrospinal fluid barrier.
- Published
- 2003
- Full Text
- View/download PDF
39. Glucose Uptake and Adenoviral Mediated GLUT1 Infection Decrease Hypoxia-induced HIF-1α Levels in Cardiac Myocytes
- Author
-
Malhotra, Ricky, Tyson, David G. W., Sone, Hirohito, Aoki, Kasunori, Kumaga, Arno K., and Brosius III, Frank C.
- Subjects
- *
HEART cells , *GLUCOSE , *HYPOXEMIA - Abstract
R. Malhotra, D. G. W. Tyson, H. Sone, K. Aoki, A. K. Kumagai and F. C. Brosius III. Glucose Uptake and Adenoviral Mediated GLUT1 Infection Decrease Hypoxia-induced HIF-1α Levels in Cardiac Myocytes. Journal of Molecular and Cellular Cardiology (2002) 34, 1063–1073. Hypoxia causes a large array of adaptive and physiological responses in all cells including cardiac myocytes. In order to elucidate the molecular effects of increased glucose flux on hypoxic cardiac myocytes we focused on the basic helix-loop-helix transcription factor, hypoxia inducible factor 1 alpha (HIF-1α), which is rapidly upregulated in hypoxic cells and elicits a number of responses including augmentation of glucose uptake. Primary cultures of neonatal rat cardiac myocytes as well as embryonic rat heart-derived myogenic H9c2 cells demonstrated a significant upregulation of HIF-1α when subjected to hypoxia of 6–8 h in the absence of glucose. Re-addition of extracellular glucose to the medium resulted in a decrease of HIF-1α levels by almost 50%. This glucose effect was blocked by addition of glycolytic inhibitors. In addition, glucose uptake and glycolysis resulted in substantial decreased levels of p53, which is regulated by HIF-1α. Adenoviral infection of cultures of cardiac myocytes with the facilitative glucose transporter, GLUT1 followed by hypoxia of 24 h also resulted in a significant reduction in the protein expression of HIF-1α compared to control vector-infected cultures. GLUT1 infected cultures also demonstrated fewer apoptotic cells and a reduction in the release of cytochrome c after hypoxia. Inhibition of the ubiquitin-proteasomal pathway by a variety of 26S proteasomal inhibitors increased HIF-1α to similar levels under both normoxic and hypoxic conditions and in the presence or absence of glucose. This result suggested that glucose induces HIF-1α degradation via a proteasomal pathway. This conclusion was substantiated by immunoprecipitation experiments of total cell extracts, which demonstrated an increase of ubiquitinated HIF-1α relative to total HIF-1α in the presence of glucose during hypoxia. Thus, glucose as well as GLUT1 overexpression diminishes hypoxia-induced HIF-1α protein via an ubiquitin-proteasomal pathway in hypoxic cardiac myocytes. This represents a novel feedback mechanism that may play an important role in adaptation of cardiac myocytes to hypoxia and ischemia. [Copyright &y& Elsevier]
- Published
- 2002
- Full Text
- View/download PDF
40. Antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin...
- Author
-
Heilig, Charles W., Kreisberg, Jeffrey I., Freytag, Svend, Murakami, Takashi, Ebina, Yousuke, Guo, Lirong, Heilig, Kathleen, Loberg, Robert, Xuan Qu, Ying Jin, Henry, Douglas, and Brosius III, Frank C.
- Subjects
- *
ANTISENSE peptides , *FIBRONECTINS , *GLUCOSE , *PHYSIOLOGY , *SECRETION - Abstract
Tests the hypothesis that antisense GLUT-1 protects mesangial cells from glucose induction of GLUT-1 and fibronectin (FN) expression. Immunoprecipitation of FN protein to measure changes in its synthesis by mesangial cells; Development of a clone of antisense GLUT-1 transduced mesangial cells.
- Published
- 2001
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.